益髓生血灵治疗β—地中海贫血症29例临床观察  

Clinical Observation on Treatment of 29 Cases of β-Mediterranean Anemia (Thalassemia) with Yisui Shengxue Ling (YSSXL)

作　　者：吴志奎[1] 黄有文[2] 王荣新[2] 蔡辉国 李承军[1] 姜葆华[1] 崔京华[1] 陈玉英[1] 吕新霞[1] 郑君[1] 陈佩贞 徐晶[3] 

机构地区：[1]中国中医研究院广安门医院分子生物学研究室,北京市宣武区北线阁5号100053 [2]中国人民解放军第三○三医院血液研究室 [3]中国医学科学院血液学研究所实验血液学重点实验室

出　　处：《中医杂志》2000年第2期90-91,共2页Journal of Traditional Chinese Medicine

基　　金：国家中医药管理局科研基金(95B102)

摘　　要：根据中医肾生髓的理论,用中药益髓生血灵在广西高发区治疗β—地中海贫血41例,其中益髓生血灵胶囊治疗29例,28例有效,用益髓生血灵新剂型(冲剂)治疗12例,全部有效。并与西药马利兰治疗β—地中海贫血作了比较分析,表明中药治疗的显著疗效和优势。并对治疗的患者进行了系统的基因分析,从基因突变与疗效关系,基因表达与调控等方面研究了疗效的分子机理,提出了中药治疗β—地中海贫血的可能机制,提出了中医肾生髓的理论是中医药治疗β—地中海贫血的理论核心的假说,并验证了它的客观性,为传统中医药治疗β—地中海贫血理论和实践提供了科学依据。Based on the TCM theory of 'kidney generates marrow', we treated 41 cases of β- Mediterranean anemia from an highly endemic area in Guangxi. Of whom, 29 cases were treated with YSSXL. 28 cases were effective: another 12 cases were treated with new form YSSXL instant granules, all effective. Comparison was made between the treatment group and a group treated with myleran. The results showed that the former group was markedly effective and superior to the latter. Systemic analysis on gene was also made in the patients, in the aspects of the relationship between genetic mutation and therapeutic effect, genetic expression and modulation, for the study of its molecular mechanism. This study also gives the possible mechanism of thalassemia treated by Chinese remedy: putting forward a hypothesis claiming that the said Chinese theory is its theoretical core. Its objectivity was identified, thus offering the scientific background for the theory and practice of thalassemia treated by traditional Chinese Medicine.

关 键 词：Β地中海贫血 中医药疗法 益髓生血灵 

分 类 号：R259.5[医药卫生—中西医结合]